Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2010

View Archived Issues

Clinical and preclinical data suggest potential of teneligliptin in diabetes

Elan Pharma reports effects of ELND-006 on Abeta in animals

Encouraging data disclosed on antidiabetes candidate TAK-875

Biolipox claims new LTC4 synthase inhibitors

Korean scientists disclose new inhibitors of Abeta neurotoxicity

Merck & Co. describes novel GPR109B receptor agonists

Novel HIF-1-alpha activators identified by sanofi-aventis

ABT-288 improves cognition in vivo

SAM-760 under clinical evaluation for treatment of AD

Clinical data on inhaled Technosphere insulin disclosed at ADA

FDA approves Lorus Therapeutics' IND for anticancer agent LOR-253

Watson Pharma licenses Itero's rFSH for female infertility

Health Canada clears phase III ReoT3D trial in head and neck cancer

Almirall presents novel S1P1 receptor agonists

Jevtana launched in U.S. for metastatic hormone-refractory prostate cancer

FDA approves Veltin gel for acne vulgaris in patients age 12 years and older

Takeda's Lampion pack approved in Japan

Geron begins phase II imetelstat trial in advanced non-small cell lung cancer

Phase II trial of interferon alfa-n3 for flu cleared in India

FDA begins NDA review for new oral rufinamide formulation

Tenofovir vaginal gel progresses in clinical trials for HIV prevention

Pfizer suspends tanezumab trials in chronic pain at request of FDA

Actelion's option to acquire Trophos depends on phase III olesoxime data

FLAP inhibitors enter phase II studies in asthma

Pharming finalizes divestment of DNage

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...